Document And Entity Information - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Mar. 25, 2026 |
Jun. 30, 2025 |
|
| Document Information [Line Items] | |||
| Entity Central Index Key | 0001583648 | ||
| Entity Registrant Name | Palvella Therapeutics, Inc. | ||
| Amendment Flag | false | ||
| Current Fiscal Year End Date | --12-31 | ||
| Document Fiscal Period Focus | FY | ||
| Document Fiscal Year Focus | 2025 | ||
| Document Type | 10-K | ||
| Document Annual Report | true | ||
| Document Period End Date | Dec. 31, 2025 | ||
| Document Transition Report | false | ||
| Entity File Number | 001-37471 | ||
| Entity Incorporation, State or Country Code | NV | ||
| Entity Tax Identification Number | 30-0784346 | ||
| Entity Address, Address Line One | 353 W. Lancaster Ave | ||
| Entity Address, Address Line Two | Suite 200 | ||
| Entity Address, City or Town | Wayne | ||
| Entity Address, State or Province | PA | ||
| Entity Address, Postal Zip Code | 19087 | ||
| City Area Code | 484 | ||
| Local Phone Number | 253-1461 | ||
| Title of 12(b) Security | Common Stock, par value $0.001 per share | ||
| Trading Symbol | PVLA | ||
| Security Exchange Name | NASDAQ | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 196.7 | ||
| Entity Common Stock, Shares Outstanding | 14,313,659 | ||
| Documents Incorporated by Reference | DOCUMENTS INCORPORATED BY REFERENCE The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December 31, 2025. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K. |
||
| Auditor Firm ID | 42 | ||
| Auditor Name | Ernst & Young LLP | ||
| Auditor Location | Philadelphia, Pennsylvania | ||
| Auditor Opinion | Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Palvella Therapeutics, Inc. (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, changes in convertible preferred stock and stockholders' equity (deficit), and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles. |